PDCD1 and non-small cell lung carcinoma: The promising therapeutic activity of ICIs in NSCLC has led the US Food and Drug Administration (FDA) to approve pembrolizumab, an antibody directed against the PD‐1 immune checkpoint molecule for the treatment of NSCLC patients whose tumors express PD‐L1 [3].